Revvity (NYSE:RVTY) Price Target Increased to $120.00 by Analysts at JPMorgan Chase & Co.

Revvity (NYSE:RVTY) had its target price raised by equities research analysts at JPMorgan Chase & Co. from $105.00 to $120.00 in a research report issued on Tuesday, Benzinga reports. The firm presently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s target price would indicate a potential downside of 4.47% from the company’s previous close.

A number of other analysts also recently commented on the stock. Barclays boosted their price objective on shares of Revvity from $115.00 to $125.00 and gave the stock an “equal weight” rating in a report on Tuesday. Bank of America boosted their price target on Revvity from $118.00 to $127.00 and gave the stock a “neutral” rating in a research note on Tuesday. SVB Leerink began coverage on Revvity in a research note on Monday, July 8th. They issued an “outperform” rating and a $125.00 price objective for the company. Leerink Partnrs upgraded Revvity to a “strong-buy” rating in a research report on Monday, July 8th. Finally, TD Cowen raised their price target on Revvity from $123.00 to $130.00 and gave the company a “buy” rating in a research report on Tuesday, April 30th. Eight analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $121.67.

Revvity Stock Up 0.0 %

RVTY opened at $125.62 on Tuesday. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.23 and a quick ratio of 1.92. Revvity has a 12 month low of $79.50 and a 12 month high of $127.88. The stock has a market capitalization of $15.50 billion, a P/E ratio of 103.79, a P/E/G ratio of 3.00 and a beta of 1.05. The business has a 50 day simple moving average of $109.09 and a 200-day simple moving average of $106.57.

Revvity (NYSE:RVTY) last released its quarterly earnings data on Monday, July 29th. The company reported $1.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.12 by $0.10. The firm had revenue of $691.70 million during the quarter, compared to analysts’ expectations of $690.33 million. Revvity had a return on equity of 7.37% and a net margin of 5.49%. Revvity’s revenue was down 2.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.21 earnings per share. On average, equities analysts anticipate that Revvity will post 4.64 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Revvity news, insider Joel S. Goldberg sold 4,000 shares of the business’s stock in a transaction dated Friday, June 7th. The stock was sold at an average price of $110.46, for a total transaction of $441,840.00. Following the completion of the sale, the insider now owns 36,900 shares of the company’s stock, valued at $4,075,974. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 0.60% of the company’s stock.

Institutional Trading of Revvity

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Parkside Financial Bank & Trust acquired a new stake in shares of Revvity in the fourth quarter worth $25,000. CENTRAL TRUST Co acquired a new position in shares of Revvity during the fourth quarter worth about $27,000. Benjamin F. Edwards & Company Inc. purchased a new stake in shares of Revvity during the 4th quarter valued at about $27,000. ORG Partners LLC purchased a new stake in shares of Revvity during the fourth quarter valued at approximately $32,000. Finally, Desjardins Global Asset Management Inc. acquired a new position in shares of Revvity during the fourth quarter worth $37,000. Institutional investors and hedge funds own 86.65% of the company’s stock.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.